Molecular Mechanisms of Melatonin in Alzheimer's Disease: Insights from Network Pharmacology and Molecular Docking
DOI:
https://doi.org/10.22317/jcms.v11i1.1713Keywords:
Alzheimer Disease, Melatonin, Molecular Docking, Network PharmacologyAbstract
Objective: This study explores melatonin's potential therapeutic effects on Alzheimer's disease (AD) using computational tools, focusing on its impact on key pathological features of AD.
Methods: We assessed ML's pharmacological properties, toxicity, and biological targets, identifying overlaps with AD-related genes. A pharmacological-target-pathology network was developed utilizing the software Cytoscape, and an analysis of protein-protein interactions (PPI) was conducted employing the STRING database. Gene Ontology (GO) and KEGG pathway enrichment analyses were conducted, followed by protein-ligand docking simulations to validate ML's interactions with key targets.
Results: ML exhibits favorable ADME properties, good solubility, and the ability to cross the blood-brain barrier, with a generally safe toxicity profile; however, caution is advised regarding neurotoxicity and respiratory toxicity. Our analysis identified 15,564 AD-related genes and 101 ML targets, with 95 shared genes. Key genes in the PPI network include EGFR, PTGS2, ERBB2, and others. GO analysis highlighted processes related to nitrogen compounds, cell proliferation, and membrane functions, particularly in serotonin receptor signaling. Molecular docking revealed ERBB2 as the strongest ML target, suggesting its potential in AD therapy.
Conclusions: This study concludes that ML may offer a promising therapeutic approach for AD by targeting multiple pathways and key proteins, such as ERBB2, and modulating biological processes related to neuronal signaling.
References
Reddy PH. A critical assessment of research on neurotransmitters in Alzheimer’s disease. Journal of Alzheimer's Disease. 2017;57(4):969-74.
Bature F, Guinn B-a, Pang D, Pappas Y. Signs and symptoms preceding the diagnosis of Alzheimer’s disease: a systematic scoping review of literature from 1937 to 2016. BMJ open. 2017;7(8):e015746.
Mahakizadeh S, Mokhtari T, Navaee F, Poorhassan M, Tajik A, Hassanzadeh G. Effects of chronic hypoxia on the expression of seladin-1/Tuj1 and the number of dark neurons of hippocampus. Journal of Chemical Neuroanatomy. 2020;104:101744.
Roy J, Tsui KC, Ng J, Fung M-L, Lim LW. Regulation of melatonin and neurotransmission in Alzheimer’s disease. International Journal of Molecular Sciences. 2021;22(13):6841.
Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet Neurology. 2010;9(1):119-28.
Chen KH, Reese EA, Kim HW, Rapoport SI, Rao JS. Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. Journal of Alzheimer's disease : JAD. 2011;26(4):755-66.
Ramalingam M, Kim S-J. Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases. Journal of Neural Transmission. 2012;119:891-910.
Olufunmilayo EO, Gerke-Duncan MB, Holsinger RD. Oxidative stress and antioxidants in neurodegenerative disorders. Antioxidants. 2023;12(2):517.
Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N. Neuroinflammation as a common feature of neurodegenerative disorders. Frontiers in pharmacology. 2019;10:1008.
Mokhtari T. Targeting autophagy and neuroinflammation pathways with plant‐derived natural compounds as potential antidepressant agents. Phytotherapy Research. 2022;36(9):3470-89.
Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre‐Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. Journal of pineal research. 2016;61(3):253-78.
Santos TCd, Gomes TM, Pinto BAS, Camara AL, Paes AMDA. Naturally occurring acetylcholinesterase inhibitors and their potential use for Alzheimer's disease therapy. Frontiers in Pharmacology. 2018;9:1192.
Kandimalla R, Reddy PH. Therapeutics of neurotransmitters in Alzheimer’s disease. Journal of Alzheimer's Disease. 2017;57(4):1049-69.
Hedayatpour A, Shiasi M, Famitafreshi H, Abolhassani F, Ebrahimnia P, Mokhtari T, et al. Co-administration of progesterone and melatonin attenuates ischemia-induced hippocampal damage in rats. Journal of molecular neuroscience. 2018;66:251-60.
Mokhtari T, Yue L-P, Hu L. Exogenous melatonin alleviates neuropathic pain-induced affective disorders by suppressing NF-κB/NLRP3 pathway and apoptosis. Scientific reports. 2023;13(1):2111.
Azizi M, Pasbakhsh P, Nadji SA, Pourabdollah M, Mokhtari T, Sadr M, et al. Therapeutic effect of perinatal exogenous melatonin on behavioral and histopathological changes and antioxidative enzymes in neonate mouse model of cortical malformation. International Journal of Developmental Neuroscience. 2018;68:1-9.
Morgese MG, Trabace L. Monoaminergic system modulation in depression and Alzheimer’s disease: a new standpoint? Frontiers in pharmacology. 2019;10:483.
Roy J, Tsui KC, Ng J, Fung ML, Lim LW. Regulation of Melatonin and Neurotransmission in Alzheimer's Disease. Int J Mol Sci. 2021;22(13).
Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Progress in neurobiology. 2008;85(3):335-53.
Zhang H, Zhang Y, Li Y, Wang Y, Yan S, Xu S, et al. Bioinformatics and network pharmacology identify the therapeutic role and potential mechanism of melatonin in AD and rosacea. Frontiers in Immunology. 2021;12:756550.
Noor F, Tahir ul Qamar M, Ashfaq UA, Albutti A, Alwashmi ASS, Aljasir MA. Network pharmacology approach for medicinal plants: review and assessment. Pharmaceuticals. 2022;15(5):572.
Li L, Yang L, Yang L, He C, He Y, Chen L, et al. Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine. Chinese Medicine. 2023;18(1):146.
Mokhtari T, Ayman EL. Molecular mechanisms of Schisandra chinensis in treating depression-neuropathic pain comorbidity by network pharmacology and molecular docking analysis. Neuroscience. 2024;555:92-105.
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017;7(1):42717.
Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic acids research. 2018;46(W1):W257-W63.
Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Data mining in proteomics: from standards to applications. 2011:291-303.
Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic acids research. 2023;51(D1):D638-D46.
Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36(8):2628-9.
Liu Y, Yang X, Gan J, Chen S, Xiao Z-X, Cao Y. CB-Dock2: Improved protein–ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic acids research. 2022;50(W1):W159-W64.
Chiquita S, Rodrigues-Neves AC, Baptista FI, Carecho R, Moreira PI, Castelo-Branco M, et al. The Retina as a Window or Mirror of the Brain Changes Detected in Alzheimer's Disease: Critical Aspects to Unravel. Molecular neurobiology. 2019;56(8):5416-35.
Mohammadi S, Zandi M, Dousti Kataj P, Karimi Zandi L. Chronic stress and Alzheimer's disease. Biotechnology and applied biochemistry. 2022;69(4):1451-8.
Shin Y, Choi SH, Kim E, Bylykbashi E, Kim JA, Chung S, et al. Blood-Brain Barrier Dysfunction in a 3D In Vitro Model of Alzheimer's Disease. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2019;6(20):1900962.
Mohammadi S, Zahmatkesh M, Asgari Y, Aminyavari S, Hassanzadeh G. Evaluation of hippocampal arylalkylamine N-acetyltransferase activity in amyloid-β neurotoxicity. Journal of molecular endocrinology. 2023;71(2).
Naseri S, Moghahi SMHN, Mokhtari T, Roghani M, Shirazi AR, Malek F, et al. Radio-protective effects of melatonin on subventricular zone in irradiated rat: decrease in apoptosis and upregulation of nestin. Journal of Molecular Neuroscience. 2017;63:198-205.
Das R, Balmik AA, Chinnathambi S. Melatonin Reduces GSK3β-Mediated Tau Phosphorylation, Enhances Nrf2 Nuclear Translocation and Anti-Inflammation. ASN neuro. 2020;12:1759091420981204.
Xu J, Gao H, Zhang L, Rong S, Yang W, Ma C, et al. Melatonin alleviates cognition impairment by antagonizing brain insulin resistance in aged rats fed a high-fat diet. Journal of pineal research. 2019;67(2):e12584.
Al-Zaqri N, Pooventhiran T, Alsalme A, Warad I, John AM, Thomas RJJoML. Structural and physico-chemical evaluation of melatonin and its solution-state excited properties, with emphasis on its binding with novel coronavirus proteins. 2020;318:114082.
Tan DX. Melatonin and brain. Current neuropharmacology. 2010;8(3):161.
Meltz ML, Reiter RJ, Herman TSJMRF, Mutagenesis MMo. Melatonin and protection from whole-body irradiation: survival studies in mice. 1999;425(1):21-7.
Sugden DJJoP, Therapeutics E. Psychopharmacological effects of melatonin in mouse and rat. 1983;227(3):587-91.
Wang F, Zhu Y, Wanggou S, Lin D, Su J, Li X, et al. A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma. Cancer letters. 2024;592:216920.
Choi HJ, Jeong YJ, Kim J, Hoe HS. EGFR is a potential dual molecular target for cancer and Alzheimer's disease. Frontiers in pharmacology. 2023;14:1238639.
Ma SL, Tang NL, Zhang YP, Ji LD, Tam CW, Lui VW, et al. Association of prostaglandin-endoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese. Neurobiology of aging. 2008;29(6):856-60.
Yao C, Liu X, Zhou Z, Xiang Y, Yuan S, Xie W, et al. Melatonin attenuates expression of cyclooxygenase-2 (COX-2) in activated microglia induced by lipopolysaccharide (LPS). Journal of toxicology and environmental health Part A. 2019;82(7):437-46.
Ma QW, Han RT, Wu ZJ, Zhou JJ, Chen MT, Zhang XZ, et al. Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson's disease. Frontiers in pharmacology. 2024;15:1363212.
Mao K, Zhang G. The role of PARP1 in neurodegenerative diseases and aging. The FEBS journal. 2022;289(8):2013-24.
Sola M, Rendon-Angel A, Rojo Martinez V, Sgrignani J, Magrin C, Piovesana E, et al. Tau protein binds to the P53 E3 ubiquitin ligase MDM2. Scientific reports. 2023;13(1):10208.
Proietti S, Cucina A, Dobrowolny G, D'Anselmi F, Dinicola S, Masiello MG, et al. Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. Journal of pineal research. 2014;57(1):120-9.
Cade BE, Gottlieb DJ, Lauderdale DS, Bennett DA, Buchman AS, Buxbaum SG, et al. Common variants in DRD2 are associated with sleep duration: the CARe consortium. Human molecular genetics. 2016;25(1):167-79.
Small GW, Noble EP, Matsuyama SS, Jarvik LF, Komo S, Kaplan A, et al. D2 dopamine receptor A1 allele in Alzheimer disease and aging. Archives of neurology. 1997;54(3):281-5.
Ugartemendia L, Bravo R, Reuter M, Castaño MY, Plieger T, Zamoscik V, et al. SLC6A4 polymorphisms modulate the efficacy of a tryptophan-enriched diet on age-related depression and social cognition. Clinical Nutrition. 2021;40(4):1487-94.
Alsallum M, Kaminskaya YP, Tsybko A, Kolosova N, Naumenko VJAiG. Patterns of Expression of the Key Genes of the BDNF System and Serotonin Receptors in the Brain of OXYS Rats in the Development of the Signs of Alzheimer’s Disease. 2023;13(2):84-93.
Giri A, Mehan S, Khan Z, Gupta GD, Narula AS. Melatonin-mediated IGF-1/GLP-1 activation in experimental OCD rats: Evidence from CSF, blood plasma, brain and in-silico investigations. Biochemical Pharmacology. 2023;217:115831.
Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast cancer research and treatment. 1998;52(1-3):261-88.
Zhang Q, Park E, Kani K, Landgraf R. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(33):13237-42.
Treisman R. Regulation of transcription by MAP kinase cascades. Current opinion in cell biology. 1996;8(2):205-15.
Strelkov IS, Davie JR. Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts. Cancer research. 2002;62(1):75-8.
Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer research. 2005;65(3):1027-34.
Mao L, Summers W, Xiang S, Yuan L, Dauchy RT, Reynolds A, et al. Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression. Molecular cancer research : MCR. 2016;14(11):1159-69.
Alokail MS, Al-Daghri NM, Mohammed AK, Vanhoutte P, Alenad A. Increased TNF α, IL-6 and ErbB2 mRNA expression in peripheral blood leukocytes from breast cancer patients. Medical oncology (Northwood, London, England). 2014;31(8):38.
Li Y, Hung SW, Zheng X, Ding Y, Zhang T, Tan Z, et al. Melatonin Inhibits Endometriosis Growth via Specific Binding and Inhibition of EGFR Phosphorylation. J Pineal Res. 2024;76(8):e70022.
Wang BJ, Her GM, Hu MK, Chen YW, Tung YT, Wu PY, et al. ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 2017;114(15):E3129-e38.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
